Increased conceptual switching by dopaminergic treatment in patients with Parkinson's disease

被引:5
|
作者
Tiedt, Hannes O. [1 ]
Ehlen, Felicitas [1 ,2 ]
Klostermann, Fabian [1 ,3 ]
机构
[1] Charite Univ Med Berlin, Dept Neurol, Motor & Cognit Grp, Campus Benjamin Franklin CBF, Hindenburgdamm 30, D-12203 Berlin, Germany
[2] Jud Krankenhaus Berlin, Dept Psychiat, Heinz Galinski Str 1, D-13347 Berlin, Germany
[3] Humboldt Univ, Berlin Sch Mind & Brain, Unter Linden 6, D-10099 Berlin, Germany
关键词
Parkinson's disease; Verbal fluency; Dopamine; Switches; Cluster; Semantic spreading activation; SPREADING-ACTIVATION THEORY; DEEP BRAIN-STIMULATION; VERBAL FLUENCY; WORKING-MEMORY; COGNITIVE PERFORMANCE; SEMANTIC ACTIVATION; DECISION-MAKING; MODULATION; LEVODOPA; OSCILLATIONS;
D O I
10.1016/j.bandc.2020.105611
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Cognitive changes including reduced word production in verbal fluency (VF) tasks are frequently observed in Parkinson's disease (PD) with ambiguous effects of dopaminergic medication on these symptoms. Here, we studied the impact of dopaminergic medication on specific cognitive components underlying VF task performance in 21 participants with PD on their regular medication and following dopamine withdrawal compared with healthy controls. We used temporal cluster analysis (TCA) to differentiate phases of VF output relating to fast automatic lexical activation ('clusters') and slower attention-demanding shifts ('switches'). Dopaminergic medication led to increased switching and, in non-alternating VF tasks, to the formation of smaller and shorter word clusters. The number of switches was correlated with higher cognitive scores and showed an inverse relationship with VF error rates. Increased switching operations during VF task performance can be interpreted in view of nigrostriatal dopaminergic roles for balancing system state versus change propensities. The additional effect on word clustering suggests a modulation of semantic spreading activation mechanisms underlying lexical search, presumably involving non-nigrostriatal, e.g., mesocortical dopaminergic networks.
引用
下载
收藏
页数:8
相关论文
共 50 条
  • [41] Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson's disease
    Baron, MS
    Dalton, WB
    MOVEMENT DISORDERS, 2003, 18 (10) : 1208 - 1209
  • [42] Subthalamic nucleus stimulation, dopaminergic treatment and impulsivity in Parkinson's disease
    Fluchere, Frederique
    Burle, Boris
    Vidal, Franck
    van den Wildenberg, Wery
    Witjas, Tatiana
    Eusebio, Alexandre
    Azulay, Jean-Philippe
    Hasbroucq, Thierry
    NEUROPSYCHOLOGIA, 2018, 117 : 167 - 177
  • [43] Arguments favoring early treatment of Parkinson's disease with dopaminergic agonists
    Rascol, O
    REVUE NEUROLOGIQUE, 1999, 155 (01) : 35 - 42
  • [44] Drug Insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease
    C Warren Olanow
    José A Obeso
    Fabrizio Stocchi
    Nature Clinical Practice Neurology, 2006, 2 : 382 - 392
  • [46] Production of dopaminergic neurons for cell therapy in the treatment of Parkinson's disease
    Peaire, AE
    Takeshima, T
    Johnston, JM
    Isoe, K
    Nakashima, K
    Commissiong, JW
    JOURNAL OF NEUROSCIENCE METHODS, 2003, 124 (01) : 61 - 74
  • [47] Autonomic symptoms and dopaminergic treatment in de novo Parkinson's disease
    Muller, B.
    Assmus, J.
    Larsen, J. P.
    Haugarvoll, K.
    Skeie, G. O.
    Tysnes, O. -B.
    ACTA NEUROLOGICA SCANDINAVICA, 2013, 127 (04): : 290 - 294
  • [48] Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson's Disease
    Redensek, Sara
    Flisar, Dusan
    Kojovic, Maja
    Kramberger, Milica Gregoric
    Georgiev, Dejan
    Pirtosek, Zvezdan
    Trost, Maja
    Dolzan, Vita
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [49] Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson's disease
    Ruggieri, S
    DePandis, MF
    Bonamartini, A
    Vacca, L
    Stocchi, F
    CLINICAL NEUROPHARMACOLOGY, 1997, 20 (03) : 204 - 209
  • [50] Earlier Dopaminergic Treatment in Parkinson's Disease Is Not Associated With Improved Outcomes
    Schneider, Ruth B.
    Lu, Xiang
    Bigian, Kevin
    McDermott, Michael P.
    MOVEMENT DISORDERS CLINICAL PRACTICE, 2019, 6 (03): : 222 - 226